Skip to main content
SpringerLink
Log in

Animal models of Charcot-Marie-Tooth disease type 1A

  • Review Article
  • Published:
NeuroMolecular Medicine Aims and scope Submit manuscript

Abstract

The most frequent genetic subtype of Charcot-Marie-Tooth disease is CMT1A, linked to chromosome 17p11.2. In the majority of cases, CMT1A is a gene dosage disease associated with a 1.5 Mb large genomic duplication. Transgenic models with extra copies of the Pm22 gene have provided formal proof that overexpression of only this candidate gene is sufficent to cause peripheral demyelination, onion bulb formation, secondary axonal loss, and progressive muscle atrophy, the pathological hallmarks of CMT1A. The transgenic CMT rat with about 1.6-fold PMP22 overexpression exhibits clinical abnormalities, such as reduced nerve conduction velocity and lower grip strength that mimick findings in CMT1A patients. Also transgenic mice, carrying yeast artifical chromosomes as Pmp22 transgenes, demonstrate the variability of disease expression as a function of increased gene dosage. Recently, the first rational experimental therapies of CMT1A were tested, using transgenic animal models. In one proof-of-principle study with the CMT rat, a synthetic antagonist of the nuclear progesterone receptor was shown to reduce PMP22 overexpression and to ameliorate the clinical severity. In another study, administration of ascorbic acid, an essential factor of in vitro myelination, prolonged the survival and restored myelination of a dysmyelinated mouse model. Application of gene expression analysis to nerve biopsies that are readily available from such CMT1A animal models might identify additional pharmacological targets.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Adlkofer K., Martini R., Aguzzi A., Zielasek J., Toyka K. V., and Suter U. (1995) Hypermyelination and demyelinating peripheral neuropathy in Pmp22-deficient mice. Nat. Genet. 11(3), 274–280.

    PubMed  CAS  Google Scholar 

  • Atanasoski S., Scherer S. S., Nave K. A., and Suter U. (2002) Proliferation of Schwann cells and regulation of cyclin D1 expression in an animal model of Charcot-Marie-Tooth disease type 1A. J. Neurosci. Res. 67(4), 443–449.

    PubMed  CAS  Google Scholar 

  • Baechner D., Liehr T., Hameister H., et al. (1995) Widespread expression of the peripheral myelin protein-22 gene (PMP22) in neural and non-neural tissues during murine development. J. Neurosci. Res. 42(6), 733–741.

    PubMed  CAS  Google Scholar 

  • Berciano J., Garcia A., Calleja J., and Combarros O. (2000) Clinico-electrophysiological correlation of extensor digitorum brevis muscle atrophy in children with Charcot-Marie-Tooth disease 1A duplication. Neuromuscul. Disord. 10(6), 419–424.

    PubMed  CAS  Google Scholar 

  • Birouk N., Gouider R., Le Guern E., et al. (1997) Charcot-Marie-Tooth disease type 1A with 17p11.2 duplication. Clinical and electrophysiological phenotype study and factors influencing disease severity in 119 cases. Brain 120(Pt 5), 813–823.

    PubMed  Google Scholar 

  • Carey D. J. and Todd M. S. (1987) Schwann cell myelination in a chemically defined medium: demonstration of a requirement for additives that promote Schwann cell extracellular matrix formation. Brain Res. 429(1), 95–102.

    PubMed  CAS  Google Scholar 

  • D'Urso D., Ehrhardt P., and Muller H. W. (1999) Peripheral myelin protein 22 and protein zero: a novel association in peripheral nervous system myelin. J. Neurosci. 19(9), 3396–3403.

    PubMed  Google Scholar 

  • Desarnaud F., Do Thi A. N., Brown A. M., et al. (1998) Progesterone stimulates the activity of the promoters of peripheral myelin protein-22 and protein zero genes in Schwann cells. J. Neurochem. 71(4), 1765–1768.

    PubMed  CAS  Google Scholar 

  • Ehrenreich H., Aust C., Krampe H., et al. (2004) Erythropoietin: novel approaches to neuroprotection in human brain disease. Metab. Brain Dis. 19(3–4), 195–206.

    PubMed  CAS  Google Scholar 

  • Ellegala D. B., Monteith S. J., Haynor D., Bird T. D. Goodkin R., and Kiot M. (2005) Characterization of genetically defined types of Charcot-Marie-Tooth neuropathies by using magnetic resonance neurography. J. Neurosurg. 102(2), 242–245.

    PubMed  Google Scholar 

  • Fortun J., Go J. C., Li J., Amici S. A., Dunn W. A., Jr., and Notterpek L. (2005) Alterations in degradative pathways and protein aggregation in a neuropathy model based on PMP22 overexpression. Neurobiol. Dis. (e-pub Nov 30; in press).

  • Gallardo E., Garcia A., Combarros O., and Berciano J. (2006) Charcot-Marie-Tooth disease type 1A duplication: spectrum of clinical and magnetic resonance imaging features in leg and foot muscles. Brain 129(Pt 2), 426–437.

    PubMed  Google Scholar 

  • Garcia C. A., Malamut R. E., England J. D., Parry G. S., Liu P., and Lupski J. R. (1995) Clinical variability in two pairs of identical twins with the Charcot-Marie-Tooth disease type 1A duplication. Neurology 45(11), 2090–2093.

    PubMed  CAS  Google Scholar 

  • Giambonini-Brugnoli G., Buchstaller J., Sommer L., Suter U., and Mantei N. (2005) Distinct disease mechanisms in peripheral neuropathies due to altered peripheral myelin protein 22 gene dosage or a Pmp22 point mutation. Neurobiol. Dis. 18(3), 656–668.

    PubMed  CAS  Google Scholar 

  • Grandis M., Leandri M., Vigo T., et al. (2004) Early abnormalities in sciatic nerve function and structure in a rat model of Charcot-Marie-Tooth type 1A disease. Exp. Neurol. 190(1), 213–223.

    PubMed  CAS  Google Scholar 

  • Grandis M. and Shy M. E. (2005) Current Therapy for Charcot-Marie-Tooth Disease. Curr. Treat. Options Neurol. 7(1), 23–31.

    PubMed  Google Scholar 

  • Guenard V., Montag D., Schachner M., and Martini R. (1996) Onion bulb cells in mice deficient for myelin genes share molecular properties with immature, differentiated non-myelinating, and denervated Schwann cells. Glia 18(1), 27–38.

    PubMed  CAS  Google Scholar 

  • Harding A. E. and Thomas P. K. (1980) The clinical features of hereditary motor and sensory neuropathy types I and II. Brain 103(2), 259–280.

    PubMed  CAS  Google Scholar 

  • Hasse B., Bosse F., Hanenberg H., and Muller H. W. (2004) Peripheral myelin protein 22 kDa and protein zero: domain specific trans-interactions. Mol. Cell Neurosci. 27(4), 370–378.

    PubMed  CAS  Google Scholar 

  • Henry E. W., Cowen J. S., and Sidman R. L. (1983) Comparison of Trembler and Trembler-J mouse phenotypes: varying severity of peripheral hypomyelination. J. Neuropathol. Exp. Neurol. 42(6), 688–706.

    PubMed  CAS  Google Scholar 

  • Huxley C., Passage E., Manson A., et al. (1996) Construction of a mouse model of Charcot-Marie-Tooth disease type 1A by pronuclear injection of human YACDNA. Hum. Mol. Genet. 5(5), 563–569.

    PubMed  CAS  Google Scholar 

  • Huxley C., Passage E., Robertson A. M., et al. (1998) Correlation between varying levels of PMP22 expression and the degree of demyelination and reduction in nerve conduction velocity in transgenic mice. Hum. Mol. Genet. 7(3), 449–458.

    PubMed  CAS  Google Scholar 

  • Ionasescu V. V. (1995) Charcot-Marie-Tooth neuropathies: from clinical description to molecular genetics. Muscle Nerve 18(3), 267–275.

    PubMed  CAS  Google Scholar 

  • Johnston J. A., Ward C. L., and Kopito R. R. (1998) Aggresomes: a cellular response to misfolded proteins. J. Cell Biol. 143(7), 1883–1898.

    PubMed  CAS  Google Scholar 

  • Keswani S. C., Leitz G. J., and Hoke A. (2004) Erythropoietin is neuroprotective in models of HIV sensory neuropathy. Neurosci. Lett. 371(2,3), 102–105.

    PubMed  CAS  Google Scholar 

  • Killian J. M., Tiwari P. S., Jacobson S., Jackson R. D., and Lupski J. R. (1996) Longitudinal studies of the duplication form of Charcot-Marie-Tooth polyneuropathy. Muscle Nerve 19(1), 74–78.

    PubMed  CAS  Google Scholar 

  • King R. H. (1999) Atlas of Peripheral Nerve Pathology, Arnold, London, pp. 73–93.

    Google Scholar 

  • Kobsar I., Hasenpusch-Theil K., Wessig C., Muller H. W., and Martini R. (2005) Evidence for macrophagemediated myelin disruption in an animal model for Charcot-Marie-Tooth neuropathy type 1A. J. Neurosci. Res. 81(6), 857–864.

    PubMed  CAS  Google Scholar 

  • Krajewski K., Lewis R. A., Fuerst D. R., et al. (2000) Neurological dysfunction and axonal degeneration in Charcot-Marie-Tooth disease type 1A. Brain 123(Pt 7), 1516–1527.

    PubMed  Google Scholar 

  • Lappe-Siefke C., Goebbels S., Gravel M., et al. (2003) Disruption of Cnp1 uncouples oligodendroglial functions in axonal support and myelination. Nat. Genet. 33(3), 366–374.

    PubMed  CAS  Google Scholar 

  • Lewis R. A., Li J., Fuerst D. R., Shy M. E., and Krajewski K. (2003) Motor unit number estimate of distal and proximal muscles in Charcot-Marie-Tooth disease. Muscle Nerve 28(2), 161–167.

    PubMed  Google Scholar 

  • Lupski J. R., de Oca-Luna R. M., Slaugenhaupt S., et al. (1991) DNA duplication associated with Charcot-Marie-Tooth disease type 1A. Cell 66(2), 219–232.

    PubMed  CAS  Google Scholar 

  • Magyar J. P., Martini R., Ruelicke T., et al. (1996) Impaired differentiation of Schwann cells in transgenic mice with increased PMP22 gene dosage. J. Neurosci. 16(17), 5351–5360.

    PubMed  CAS  Google Scholar 

  • Mansuy I. M. and Bujard H. (2000) Tetracycline-regulated gene expression in the brain. Curr. Opin. Neurobiol. 10(5), 593–596.

    PubMed  CAS  Google Scholar 

  • Matsunami N., Smith B., Ballard L., et al. (1992) Peripheral myelin protein-22 gene maps in the duplication in chromosome 17p11.2 associated with Charcot-Marie-Tooth 1A. Nat. Genet. 1(3), 176–179.

    PubMed  CAS  Google Scholar 

  • Melcangi R. C., Magnaghi V., Cavarretta I., et al. (1999) Progesterone derivatives are able to influence peripheral myelin protein 22 and P0 gene expression: possible mechanisms of action. J. Neurosci. Res. 56(4), 349–357.

    PubMed  CAS  Google Scholar 

  • Nave K.-A. and Suter U. (2004) Neurological mouse mutants: a moleculargenetic analysis of myelin proteins, in Neuroglial Cells, 2nd ed., Kettenmann H., and Ransom B., eds., Oxford University Press, New York, pp. 532–549.

    Google Scholar 

  • Niemann S., Sereda M. W., Suter U., Griffiths I. R., and Nave K. A. (2000) Uncoupling of myelin assembly and schwann cell differentiation by transgenic overexpression of peripheral myelin protein 22. J. Neurosci. 20(11), 4120–4128.

    PubMed  CAS  Google Scholar 

  • Nobbio L., Mancardi G., Grandis M., et al. (2001) PMP22 transgenic dorsal root ganglia cultures show myelin abnormalities similar to those of human CMT1A. Ann. Neurol. 50(1), 47–55.

    PubMed  CAS  Google Scholar 

  • Norreel J. C., Jamon M., Riviere G., Passage E., Fontes M., and Clarac F. (2001) Behavioural profiling of a murine Charcot-Marie-Tooth disease type 1A model. Eur. J. Neurosci. 13(8), 1625–1634.

    PubMed  CAS  Google Scholar 

  • Norreel J. C., Vinay L., Fontes M., and Clarac F. (2003) Close relationship between motor impairments and loss of functional motoneurons in a Charcot-Marie-Tooth type 1A model. Neuroscience 116(3), 695–703.

    PubMed  CAS  Google Scholar 

  • Notterpek L., Ryan M. C., Tobler A. R., and Shooter E. M. (1999) PMP22 accumulation in aggresomes: implications for CMT1A pathology. Neurobiol. Dis. 6(5), 450–460.

    PubMed  CAS  Google Scholar 

  • Passage E., Norreel J. C., Noack-Fraissignes P., et al. (2004) Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease. Nat. Med. 10(4), 396–401.

    PubMed  CAS  Google Scholar 

  • Patel P. I., Roa B. B., Welcher A. A., et al. (1992) The gene for the peripheral myelin protein PMP-22 is a candidate for Charcot-Marie-Tooth disease type 1A. Nat. Genet. 1(3), 159–165.

    PubMed  CAS  Google Scholar 

  • Perea J., Robertson A., Tolmachova T., et al. (2001) Induced myelination and demyelination in a conditional mouse model of Charcot-Marie-Tooth disease type 1A. Hum. Mol. Genet. 10(10), 1007–1018.

    PubMed  CAS  Google Scholar 

  • Podratz J. L., Rodriguez E., and Windebank A. J. (2001) Role of the extracellular matrix in myelination of peripheral nerve. Glia 35(1), 35–40.

    PubMed  CAS  Google Scholar 

  • Podratz J. L., Rodriguez E. H., and Windebank A. J. (2004) Antioxidants are necessary for myelination of dorsal root ganglion neurons, in vitro. Glia 45(1), 54–58.

    PubMed  Google Scholar 

  • Raeymaekers P., Timmerman V., Nelis E., et al. (1991) Duplication in chromosome 17p11.2 in Charcot-Marie-Tooth neuropathy type 1a (CMT 1a). The HMSN Collaborative Research Group. Neuromuscul. Disord. 1(2), 93–97.

    PubMed  CAS  Google Scholar 

  • Robertson A. M., Huxley C., King R. H., and Thomas P. K. (1999) Development of early postnatal periphyeral nerve abnormalities in Trembler-J and PMP22 transgenic mice. J. Anat. 195(Part 3), 331–339.

    PubMed  Google Scholar 

  • Robertson A. M., Perea J., McGuigan A., et al. (2002) Comparison of a new pmp22 transgenic mouse line with other mouse models and human patients with CMT1A. J. Anat. 200(4), 377–390.

    PubMed  CAS  Google Scholar 

  • Sereda M. W., Griffiths I., Puhlhofer A., et al. (1996) A transgenic rat model of Charcot-Marie-Tooth disease. Neuron 16(5), 1049–1060.

    PubMed  CAS  Google Scholar 

  • Sereda M. W., Meyer zu Horste G., Suter U., Uzma N., and Nave K. A. (2003) Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT1A). Nat. Med. 9(12), 1533–1537.

    PubMed  CAS  Google Scholar 

  • Sherman D. L. and Brophy P. J. (2005) Mechanisms of axon ensheathment and myelin growth. Nat. Rev. Neurosci. 6(9), 683–690.

    PubMed  CAS  Google Scholar 

  • Shy M. E. (2004) Charcot-Marie-Tooth disease: an update. Curr. Opin. Neurol. 17(5), 579–585.

    PubMed  CAS  Google Scholar 

  • Shy M. E., Lupski J. R., Chance P. F., Klein C. J., and Dyck P. J. (2005) Hereditary motor and sensory neuropathies: an overview of clinical, genetic, electrophysiologic, and pathologic features, in Peripheral Neuropathy, vol. 2, P. J. Dyck P. J. and Thomas P. K., Philadelphia, Elsevier Saunders, pp. 1623–1658.

    Google Scholar 

  • Siren A. L., Fratelli M., Brines M., et al. (2001) Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc. Natl. Acad. Sci. USA 98(7), 4044–4049.

    PubMed  CAS  Google Scholar 

  • Suter U., Moskow J. J., Welcher A. A., et al. (1992a) A leucine-to-proline mutation in the putative first transmembrane domain of the 22-kDa peripheral myelin protein in the trembler-J mouse. Proc. Natl. Acad. Sci. USA 89(10), 4382–4386.

    PubMed  CAS  Google Scholar 

  • Suter U., Welcher A. A., Ozcelik T., et al. (1992b) Trembler mouse carries a point mutation in a myelin gene. Nature 356(6366), 241–244.

    PubMed  CAS  Google Scholar 

  • Suter U. and Scherer S. S. (2003) Disease mechanisms in inherited neuropathies. Nat. Rev. Neurosci. 4(9), 714–726.

    PubMed  CAS  Google Scholar 

  • Timmerman V., Nelis E., Van Hul W., et al. (1992) The peripheral myelin protein gene PMP-22 is contained within the Charcot-Marie-Tooth disease type 1A duplication. Nat. Genet. 1(3), 171–175.

    PubMed  CAS  Google Scholar 

  • Tobler A. R., Notterpek L., Naef R., Taylor V., Suter U., and Shooter E. M. (1999) Transport of Trembler-J mutant peripheral myelin protein 22 is blocked in the intermediate compartment and affects the transport of the wild-type protein by direct interaction. J. Neurosci. 19(6), 2027–2036.

    PubMed  CAS  Google Scholar 

  • Valentijn L. J., Baas F., Wolterman R. A., Hoogendijk J. E., van den Bosch N. H., Zorn I., Gabreels-Festen A. W., de Visser M. and Bolhuis P. A. (1992a) Identical point mutations of PMP-22 in Trembler-J mouse and Charcot-Marie-Tooth disease type 1A. Nat. Genet. 2(4), 288–291.

    PubMed  CAS  Google Scholar 

  • Valentijn L. J., Bolhuis P. A., Zorn I., et al. (1992b) The peripheral myelin gene PMP-22/GAS-3 is duplicated in Charcot-Marie-Tooth disease type 1A. Nat. Genet. 1(3), 166–170.

    PubMed  CAS  Google Scholar 

  • Vigo T., Nobbio L., Hummelen P. V.. et al. (2005) Experimental Charcot-Marie-Tooth type 1A: a cDNA microarrays analysis. Mol. Cell. Neurosci. 28(4), 703–714.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurogenetics, Max-Planck-Institute of Experimental Medicine, Göttingen, Germany

    M. W. Sereda & K. -A. Nave

  2. Center of Neurology, University of Göttingen, Germany

    M. W. Sereda

Authors
  1. M. W. Sereda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. -A. Nave
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K. -A. Nave.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sereda, M.W., Nave, K.A. Animal models of Charcot-Marie-Tooth disease type 1A. Neuromol Med 8, 205–215 (2006). https://doi.org/10.1385/NMM:8:1-2:205

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1385/NMM:8:1-2:205

Index Entries

Search

Navigation